| Company Name | Fiscal Year | EPS (Actual) | EPS (Estimated) | Revenue (Actual) | Revenue (Estimated) | Exchange | |||
|---|---|---|---|---|---|---|---|---|---|
| Loading past events... | |||||||||
|
Tuesday - Mar 28, 2017 |
|||||||||
|
Laureate Education
LAUR
|
- | $0.27 | $0.29 | $1.18B | $3.85B |
NASDAQ |
|||
|
Carnival Corporation & plc
CUK
|
Q1 FY17 | $0.38 | - | $3.79B | - |
NYSE |
|||
| Q1 FY17 | $0.38 | $0.35 | $3.79B | $3.49B |
NYSE |
||||
| Q1 FY17 | $0.38 | $0.37 | $1.04B | $1.02B |
NYSE |
||||
|
FactSet Research Systems
FDS
|
Q2 FY17 | $1.81 | $1.80 | $294.35M | $292.77M |
NYSE |
|||
|
Verint Systems
VRNT
|
Q4 FY17 | $0.90 | $0.86 | $295.86M | $282.71M |
NASDAQ |
|||
|
Ollie's Bargain Outlet Holdings
OLLI
|
Q4 FY16 | $0.39 | $0.35 | $283.36M | $254.33M |
NASDAQ |
|||
|
Dave & Buster's Entertainment
PLAY
|
- | $0.63 | $0.59 | $270.18M | $253.04M |
NASDAQ |
|||
|
ReneSola Ltd
SOL
|
Q4 FY16 | -$1.26 | -$0.80 | $232.07M | $252.38M |
NYSE |
|||
|
Centrus Energy
LEU
|
- | -$0.90 | - | $136.50M | - |
NYSE |
|||
|
Sypris Solutions
SYPR
|
Q4 FY16 | -$0.23 | - | $19.97M | - |
NASDAQ |
|||
|
New York City REIT
NYC
|
- | -$3.51 | - | $14.64M | - |
NYSE |
|||
|
Paltalk
PALT
|
Q4 FY16 | $0.15 | - | $13.18M | - |
NASDAQ |
|||
|
Canterbury Park Holding
CPHC
|
- | $0.16 | - | $11.60M | - |
NASDAQ |
|||
|
Sonnet BioTherapeutics Holdings
SONN
|
- | -$291.20 | -$72.80 | $9.86M | - |
NASDAQ |
|||
|
Stabilis Solutions
SLNG
|
- | -$1.64 | - | $9.40M | - |
NASDAQ |
|||
|
DSS
DSS
|
Q4 FY16 | $0.04 | - | $5.79M | - |
AMEX |
|||
|
Creative Realities
CREX
|
- | -$1.80 | - | $5.50M | - |
NASDAQ |
|||
|
Ramaco Resources
METC
|
- | -$0.04 | - | $3.75M | - |
NASDAQ |
|||
|
IZEA Worldwide
IZEA
|
Q4 FY16 | -$1.36 | -$1.12 | $7.43M | $920K |
NASDAQ |
|||
Splash Beverage Group
SBEV
|
- | - | - | $316.59K | - |
AMEX |
|||
|
Cyclacel Pharmaceuticals
CYCC
|
Q4 FY16 | -$206.90 | -$218.89 | $277K | $296.23K |
NASDAQ |
|||
|
Mill City Ventures III
MCVT
|
- | $0.16 | - | $273.22K | - |
NASDAQ |
|||
|
Organogenesis Holdings
ORGO
|
- | -$0.02 | - | $61.08K | - |
NASDAQ |
|||
|
Galectin Therapeutics
GALT
|
Q4 FY16 | -$0.13 | -$0.16 | - | - |
NASDAQ |
|||
| Show 15 more companies | |||||||||
